Recent Headlines
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Announces the Granting of European Patent for New Type of Cardiovascular Plaque Clearing Drug SP-1000
Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Pharma Strategically Advances Its Promising Alzheimer's Drug
Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan... - January 09, 2008 - Samaritan Pharmaceuticals
FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study
The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals
Samaritan Expands Revenue Opportunities with Marketing Authorization Approval for HIV Drug Amphocil in Cyprus
Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health... - January 03, 2008 - Samaritan Pharmaceuticals
Actors Studio's Anna Strasberg Joins Samaritan Advisory Board of Directors
Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals
EUSA Pharma Signs Exclusive Distribution Agreement with Samaritan for Anesthetic Pain Patch to Launch and Sell in Greece and Cyprus
Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals
Samaritan Presented Favorable Caprospinol Data at Alzheimer's Drug Development Summit
In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals
World-Renowned Physician and HIV Researcher Joins Samaritan's Advisory Board
Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals
Samaritan Licenses Tumor Inhibiting Cancer Drugs That Also Distinguish Cancerous Tumors to Improve on Chemotherapy
Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals
Samaritan Licenses Method to Identify Novel Anti-Tumor Drugs to Increase Cancer Compounds in Pipeline
Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals
Blue Sky Biotech, Inc Appoints Scott Gridley, Ph.D., as Senior Research Scientist
Blue Sky Biotech, Inc. announced the June 1st appointment of Scott Gridley, Ph.D., as Senior Research Scientist. Dr. Gridley previously worked for five years in the metabolic diseases division of Sandoz Research Institute (now Novartis Institutes for BioMedical Research) where he was involved in... - August 15, 2006 - Blue Sky Biotech, Inc.
Blue Sky Biotech, Inc Names Dr. Norman Garceau, Former Scientist at Pfizer Global Research and Development, as Chief Scientific Officer
Blue Sky Biotech, Inc. announced the Feb 1st appointment of Norman Garceau, Ph.D., as Chief Scientific Officer. Dr. Garceau previously worked in early drug discovery at the Pfizer Research Technology Center (Cambridge, MA) from 1999 to 2006, engaged in a range of activities that included gene cloning and expression profiling, cell biology, assay development, and lead discovery. - March 15, 2006 - Blue Sky Biotech, Inc.